These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9924488)

  • 1. Palivizumab (Synagis) for prevention of RSV infection.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488
    [No Abstract]   [Full Text] [Related]  

  • 2. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motavizumab for the prevention of respiratory syncytial virus infection in infants.
    Gill MA; Welliver RC
    Expert Opin Biol Ther; 2009 Oct; 9(10):1335-45. PubMed ID: 19764889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synagis revisited.
    Med Lett Drugs Ther; 2001 Feb; 43(1098):13-4. PubMed ID: 11182803
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential impact of palivizumab on pediatric airway reconstruction.
    Emerick K; Cunningham M; Hartnick C
    Am J Otolaryngol; 2006; 27(1):9-12. PubMed ID: 16360816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 10. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questions about palivizumab (Synagis).
    Eppes SC
    Pediatrics; 1999 Feb; 103(2):534-5; author reply 535-6. PubMed ID: 10026068
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of bronchiolitis.
    Pringle CR
    Paediatr Respir Rev; 2000 Sep; 1(3):228-34. PubMed ID: 12531084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questions about palivizumab (Synagis).
    Lee SL; Robinson JL
    Pediatrics; 1999 Feb; 103(2):535; author reply 535-6. PubMed ID: 10026069
    [No Abstract]   [Full Text] [Related]  

  • 19. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synagis: an anti-RSV monoclonal antibody.
    Driver LC; Oertel MD
    Pediatr Nurs; 1999; 25(5):527-30. PubMed ID: 12024401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.